The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Preoperative pembrolizumab for MSI high, EBV positive or PD-L1 positive locally advanced gastric cancer followed by surgery and adjuvant chemoradiation with pembrolizumab: Interim results of a phase 2 multi-center trial (NCT03257163).
 
Timothy Kennedy
No Relationships to Disclose
 
Mihir Maheshkumar Shah
No Relationships to Disclose
 
Haejin In
No Relationships to Disclose
 
Jennifer W. Chuy
No Relationships to Disclose
 
Dirk F. Moore
No Relationships to Disclose
 
David A. Kooby
No Relationships to Disclose
 
Rafi Kabarriti
No Relationships to Disclose
 
Stephen M. Szabo
No Relationships to Disclose
 
Howard S. Hochster
Consulting or Advisory Role - Amgen; AstraZeneca; Bayer; Elion Oncology; Genentech; Merck
 
Salma K. Jabbour
Consulting or Advisory Role - IMX Medical Reviewer; Merck Sharp & Dohme; Syntactx
Research Funding - Merck Sharp & Dohme (Inst); NCI (Inst)
Travel, Accommodations, Expenses - Merck Sharp & Dohme